DyNAbind and Almirall enter new collaboration
Dresden/Barcelona. DyNAbind GmbH and Almirall, a leading skin-health focused pharmaceutical company based in Barcelona (Spain) have entered into a collaboration for compound screening based on DyNAbind’s proprietary DNA-encoded library (DEL) technology. This new partnership aims at discovering novel drug candidates for treating dermatological inflammation.
Michael Thompson, Ph.D, co-founder and CEO of DyNAbind, explains the importance of this deal: “Relevant disease targets of dermatolocial conditions are oftentimes difficult to drug. That’s the reason why diseases like psoriasis to date still represent a huge unmet clinical need and significant burden for patients. We are excited about this new collaboration and the possibility of working together with the Almirall team to help improve the lives of these patients.”
Bhushan Hardas, MD, MBA, CSO, Almirall said: “This exciting collaboration offers an opportunity to discover new drug candidates to develop the right therapies for patients to help them realize their hopes and dreams. We are happy to collaborate with DyNAbind GmbH in this new step.”
Financial terms of the collaboration agreement were not disclosed.
For further information please visit the Almirall website at: https://www.almirall.com/
+49 (0)351 7999 2923